Miller George, Biernacki Peter, Kemeny Nancy E, Gonen Mithat, Downey Robert, Jarnagin William R, D'Angelica Michael, Fong Yuman, Blumgart Leslie H, DeMatteo Ronald P
Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.
J Am Coll Surg. 2007 Aug;205(2):231-8. doi: 10.1016/j.jamcollsurg.2007.04.039. Epub 2007 Jun 27.
Surgical resection of isolated hepatic or pulmonary colorectal metastases prolongs survival in selected patients. But the benefits of resection and appropriate selection criteria in patients who develop both hepatic and pulmonary metastases are ill defined.
Data were prospectively collected from 131 patients with colorectal cancer who underwent resection of both hepatic and pulmonary metastases over a 20-year period. Median followup was 6.6 years from the time of resection of the primary tumor. Patient, treatment, and outcomes variables were analyzed using log-rank, Cox regression, and Kaplan-Meier methods.
The site of first metastasis was the liver in 65% of patients, the lung in 11%, and both simultaneously in 24%. Multiple hepatic metastases were present in 51% of patients, and multiple pulmonary metastases were found in 48%. Hepatic lobectomy or trisegmentectomy was required in 61% of patients; most lung metastases (80%) were treated with wedge excisions. Median survival rates from resection of the primary disease, first site of metastasis, and second site of metastasis were 6.9, 5.0, and 3.3 years, respectively. After resection of disease at the second site of metastasis, the 1-, 3-, 5-, and 10-year disease-specific survival rates were 91%, 55%, 31%, and 19%, respectively. An analysis of prognostic factors revealed that survival was significantly longer when the disease-free interval between the development of the first and second sites of metastases exceeded 1 year, in patients with a single liver metastasis, and in patients younger than 55 years old.
Surgical resection of both hepatic and pulmonary colorectal metastases is associated with prolonged survival in selected patients. Patients with a longer disease-free interval between metastases and those with single liver lesions had the best outcomes.
孤立性肝或肺结直肠癌转移灶的手术切除可延长部分患者的生存期。但对于同时发生肝和肺转移的患者,手术切除的获益及合适的选择标准尚不明确。
前瞻性收集了131例在20年期间接受肝和肺转移灶切除的结直肠癌患者的数据。自原发性肿瘤切除时起,中位随访时间为6.6年。采用对数秩检验、Cox回归和Kaplan-Meier方法分析患者、治疗及结局变量。
65%的患者首发转移部位为肝脏,11%为肺,24%为同时发生。51%的患者存在多发肝转移,48%的患者存在多发肺转移。61%的患者需要行肝叶切除术或三段切除术;大多数肺转移(80%)采用楔形切除术治疗。原发性疾病切除、首发转移部位切除及第二转移部位切除后的中位生存率分别为6.9年、5.0年和3.3年。在第二转移部位疾病切除后,1年、3年、5年和10年的疾病特异性生存率分别为91%、55%、31%和19%。预后因素分析显示,当第一和第二转移部位出现之间的无病间期超过1年时、单发性肝转移患者以及年龄小于55岁的患者,生存期显著延长。
对选定的患者进行肝和肺结直肠癌转移灶的手术切除可延长生存期。转移灶之间无病间期较长的患者以及单发肝转移灶患者预后最佳。